|
gptkbp:instanceOf
|
gptkb:synthetic_cannabinoid
|
|
gptkbp:actsOn
|
CB1 receptor agonist
CB2 receptor agonist
|
|
gptkbp:binding_affinity_(CB1)
|
0.69 nM
|
|
gptkbp:binding_affinity_(CB2)
|
1.2 nM
|
|
gptkbp:CASNumber
|
619294-47-2
|
|
gptkbp:category
|
gptkb:recreational_drug
gptkb:substance_abuse
gptkb:naphthoylindole
gptkb:cannabinoid_receptor_agonist
|
|
gptkbp:chemicalFormula
|
C24H23NO
|
|
gptkbp:discoveredBy
|
gptkb:John_W._Huffman
|
|
gptkbp:effect
|
psychoactive
cannabimimetic
|
|
gptkbp:firstSynthesized
|
early 2000s
|
|
gptkbp:IUPACName
|
(4-methyl-1-naphthalenyl)(1-pentyl-1H-indol-3-yl)-methanone
|
|
gptkbp:legal_status_in_UK
|
Class B drug
|
|
gptkbp:legalStatus
|
Schedule I controlled substance
|
|
gptkbp:molecularWeight
|
341.45 g/mol
|
|
gptkbp:namedAfter
|
gptkb:John_W._Huffman
|
|
gptkbp:not_approved_for
|
medical use
|
|
gptkbp:relatedTo
|
gptkb:JWH-018
gptkb:JWH-073
|
|
gptkbp:routeOfAdministration
|
oral
inhalation
|
|
gptkbp:status
|
not scheduled under UN conventions
|
|
gptkbp:used_in
|
synthetic cannabis products
|
|
gptkbp:usedFor
|
gptkb:scientific_research
|
|
gptkbp:bfsParent
|
gptkb:JWH_cannabinoids
|
|
gptkbp:bfsLayer
|
6
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
JWH-122
|